Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin
2012 (English)In: Clinical Biochemistry, ISSN 0009-9120, E-ISSN 1873-2933, Vol. 45, no 7-8, 552-555 p.Article in journal (Refereed) Published
OBJECTIVES: To estimate the possible economic effects of a sequential testing strategy with F-calprotectin to minimize colonoscopies.
DESIGN AND METHODS: Retrospective study in a third party payer perspective. The costs were calculated from initial F-calprotectin test results of 3639 patients. Two cut-off levels were used: 50μg/g feces and 100μg/g feces, respectively. The cost-effectiveness of the testing strategy was estimated through the short-term cost avoidance and reduction in demand for colonoscopies.
RESULTS: The estimated demand for colonoscopies was reduced by 50% with the 50μg/g cut-off and 67% with the 100μg/g cut-off. This corresponded to a cost avoidance of approximately €1.57million and €2.13million, respectively.
CONCLUSIONS: The use of F-calprotectin as a screening test substantially could reduce the number of invasive measurements necessary in the diagnostic work-up of patients with suspected IBD, as well as the associated costs.
Place, publisher, year, edition, pages
2012. Vol. 45, no 7-8, 552-555 p.
cost-effectiveness, diagnostic tests, health care costs, inflammatory bowel disease, irritable bowel syndrome, calprotectin
Other Clinical Medicine
Research subject Biomedical Laboratory Science
IdentifiersURN: urn:nbn:se:uu:diva-120552DOI: 10.1016/j.clinbiochem.2011.10.015ISI: 000303553300008OAI: oai:DiVA.org:uu-120552DiVA: diva2:303558
Original title of the manuscript: Ruling out IBD: The cost-effectiveness of pre-endoscopic screening with F-calprotectin2010-03-122010-03-122012-05-30Bibliographically approved